Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Using CAR T cells for the treatment of acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 170

Prof Claudia Rossig - Universität Münster, Münster, Germany

Prof Claudia Rossig talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the use of CAR T cell therapy in patients with acute lymphoblastic leukaemia (ALL).

She states the recent approval for this type of therapy for children and adolescents with refractory ALL, however, further improvement to multimodal therapies is needed and the incorporation of CAR T cell therapy in the first- and second-line setting.

Prof Rossig also states the common side effects associated with this therapy and the possibility of applying this therapy to T-cell ALL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation